SULFONIC ESTER DERIVATIVES AND PROCESS FOR THEIR PREPARATION
申请人:TAIHO PHARMACEUTICAL COMPANY LIMITED
公开号:EP0117876A1
公开(公告)日:1984-09-12
Sulfonic ester derivatives represented by generalformu- la (I), wherein R, represents hydrogen, C1-4 alkyl or C-4 alkoxy, A represents (II), (wherein R2 and R3 each represent C1-4 alkyl) or (III), (wherein R4 and R5 each represent C1-4 alkyl, or they may be connected to each other to form C4-6 cycloalkyl together with the adjacent carbon atom), and represents an integer of 1 to 3, and a process for their preparation.
2- (1, t- and c-4-Dialkylcyclohex-r-1-yl) -2-oxoethyl arenesulfonates, 2- (4, 4-dialkylcyclohex-1-yl) -2-oxoethyl arenesulfonates and related compounds were synthesized and evaluated for esteraseand chymotrypsin-inhibitory activities in vitro and for hypolipidemic effect in vivo. The transisomers of 2- (1, 4-dialkylcyclohex-1-yl) -2-oxoethyl arenesulfonates showed much more potent esterase-inhibitory action (about 13 to 6200 times) than the cis-isomers as well as more potent hypolipidemic action (about 1.5 to 10 times) but the chymotrypsin-inhibitory actions of the two isomers were similarly low. On the other hand, the 2-oxoethyl arenesulfonates having a 4, 4- disubstituted cyclohexane ring mostly exhibited potent esterase-inhibitory action (order of IC50; 10-8 to 10-9M) and marked hypolipidemic effect (78% to 95% reductions of plasma triglyceride).